- Stocks
- Financials
- Biogen Pharmach
Biogen Pharmach share price
NSE: BIOGENFinancialsCapital Markets
Biogen Pharmach at a glance
With a market capitalisation of ₹34 Cr, it ranks 3313th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Financials sector; its industry is Capital Markets.
Its return on equity was −0.3% in FY25.
Key numbers
- Market cap
- ₹34 CrRank 3313 on NSE
- Price to book
- 0.68×FY25
- EPS (TTM)
- ₹0.00to Q1 FY27
- ROE
- −0.3%FY25
- ROCE
- −0.3%FY25
- Net profit margin
- 0.0%FY25
- Book value / share
- ₹1.41FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Biogen Pharmach quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Revenue YoY | — | — | — | — | — | — | — | — |
| Net profit | −₹1 Cr | −₹0 Cr | ₹1 Cr | ₹1 Cr | −₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr |
| Net profit YoY | −238.9% | −616.7% | +59.5% | — | — | — | −130.5% | −83.6% |
| Net margin | — | — | — | — | — | — | — | — |
| EPS | −₹0.02 | ₹0.00 | ₹0.02 | ₹0.01 | −₹0.01 | ₹0.01 | ₹0.00 | ₹0.00 |
Biogen Pharmach financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹2 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Operating profit | −₹0 Cr | −₹2 Cr | −₹0 Cr | ₹0 Cr | ₹2 Cr | −₹0 Cr |
| Net profit | −₹0 Cr | −₹2 Cr | −₹0 Cr | ₹0 Cr | ₹2 Cr | −₹0 Cr |
| EPS (₹) | ₹0.00 | −₹0.02 | ₹0.00 | ₹0.01 | ₹0.03 | ₹0.00 |
| Cash from operations | −₹1 Cr | ₹4 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | −₹1 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹56 Cr | ₹54 Cr | ₹54 Cr | ₹55 Cr | ₹57 Cr | ₹92 Cr |
Biogen Pharmach shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 18 May 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Domestic institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-institutions | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Biogen Pharmach vs peers
The listed Financials companies nearest to Biogen Pharmach by market capitalisation.
Ask anything about Biogen Pharmach
Pivot answers on the live chart with evidence you can check, and tests strategies against BIOGEN's own history. Try: “Why has BIOGEN moved over the last three months?” · “Backtest a 50-day moving-average crossover on BIOGEN over five years” · “Compare BIOGEN with SYLPH on margins and valuation”
Frequently asked questions about Biogen Pharmach
What is the market cap of Biogen Pharmach?
Biogen Pharmach's market capitalisation is ₹34 Cr (₹34 Cr) at the 19 Oct 2026 close, ranking 3313th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Biogen Pharmach?
Return on equity was −0.3% in FY25 and return on capital employed was −0.3% in FY25 (standalone figures).
What is the shareholding pattern of Biogen Pharmach?
As of 30 Jun 2026: domestic institutions 0.00%, non-institutions 100.00%.
Who are Biogen Pharmach's competitors?
The listed Financials companies closest to Biogen Pharmach by market cap are Sylph Ind, Supra Trends, Glance Fin, Sumedha Fiscal, Swasti Vinayaka and Yamini Invt.
Is Biogen Pharmach a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Biogen Pharmach's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BIOGEN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Financials stocks · companies starting with B · all NSE stocks · this page as text